View Post

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: oaoa.com Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen trial to investigate the safety and efficacy of Hyleukin-7™, their T cell amplifier, in combination with Merck’s anti PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory or relapsed triple-negative breast …

View Post

How destroying a tumor promoter could lead to new cancer treatments

In In The News by Barbara Jacoby

By: Catharine Paddock PhD From: medicalnewstoday.com Scientists have cracked a cell mechanism that drives tumor formation in most types of cancer. This finding could lead to much-needed new therapies for cancer, including the hard-to-treat triple-negative breast cancer. The discovery concerns the molecular activity of the tumor suppressor protein p53. This protein sits inside the nucleus of the cell and protects …

View Post

FDA Approves First Immunotherapy Drug for Triple-Negative Breast Cancer

In In The News by Barbara Jacoby

By: Kristen Fischer From: healthline.com Until now, people with inoperable triple-negative breast cancer had one treatment option: chemotherapy. But this month, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the first immunotherapy treatment for breast cancer. It combines the drug atezolizumab (Tecentriq) with a form of chemotherapy. This development is big news because the drug garnered the …

View Post

Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

In Clinical Trials by Barbara Jacoby

Source: Immunomedics From: globenewswire.com Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data from the Phase 2 study of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC) were published on NEJM.org as part of the February 21 print issue of the New England …

View Post

Compound Found in Olives May Help Prevent Deadly Type of Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Rosa Gonzalez-Lamas From: oliveoiltimes.com A chemical found in both olives and extra virgin olive oil may be useful as an alternative therapy for the prevention of triple-negative breast cancer, according to research conducted by Spain’s University of Jaén. The researchers have confirmed the chemopreventive properties that hydroxytyrosol might have in the treatment of this disease. Hydroxytyrosol is a type …

View Post

PrimeVax Immuno-Oncology Receives IND Permission From FDA

In Clinical Trials by Barbara Jacoby

Source: PrimeVax Immuno-Oncology, Inc. From: prnewswire.com PrimeVax Immuno-Oncology, Inc. announced today that the company has successfully received their Investigational New Drug (IND) Application permission from the FDA to begin running their first human clinical trial. “Our goal is simple: treat melanoma patients who have exhausted their options,” states Tony Chen, PrimeVax’s CEO. “It has been a long road, but we …

View Post

Researchers identify potential target for new breast cancer treatments

In In The News by Barbara Jacoby

Source: https://www.kcl.ac.uk From: news-medical.net Researchers from the School of Basic & Medical Biosciences have identified a potential target that could lead to new treatments for triple negative breast cancer. One in five patients with breast cancer are diagnosed with triple negative breast cancer, a cancer type where tumour cells don’t have receptors for oestrogen and progesterone, or the Her2 protein. …

View Post

CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

In Clinical Trials by Barbara Jacoby

News provided by: CytRx Corporation From: prnewswire.com This New Trial Represents the Third NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a …